Form 4: Hims & Hers Health Chief Legal Officer Sells Shares Under 10b5-1 Plan

Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc., sold 2,502 shares of Class A Common Stock at a price of $17.33 per share on May 28, 2024, under a pre-arranged trading plan.

Summary

• On May 28, 2024, Soleil Boughton, the Chief Legal Officer of Hims & Hers Health, Inc., sold 2,502 shares of Class A Common Stock.
• The sale was executed at a price of $17.33 per share.
• Following the transaction, Boughton directly owns 156,855 shares of Hims & Hers Health, Inc.
• The sale was conducted under a Rule 10b5-1 trading plan adopted by Boughton on September 10, 2023.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to an insider stock sale under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment about the company's prospects.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This Form 4 filing is a routine disclosure of insider trading activity. It is common for executives to set up 10b5-1 trading plans to sell shares over time to avoid accusations of trading on inside information. The sale itself doesn't necessarily indicate a negative outlook for the company.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies and their executives.
• The use of 10b5-1 trading plans is a common method for corporate insiders to sell shares while mitigating the risk of insider trading allegations.
• Comparable companies such as Teladoc Health and GoodRx also have executives who utilize 10b5-1 plans, and their Form 4 filings are publicly available for comparison.

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates